RxDoctor Payments DataLook up a doctor →

Rebecca Callis, MD

Rheumatology · Florence, KYNPI 1659597755

Payments from drug & device makers

$271,537in general payments, 2019–2025

Across 807 payments — averaging $336.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$132K
  • Janssen Scientific Affairs, LLC$109K
  • AbbVie$18K
  • Novartis$6K
  • UCB, Inc.$2K
  • Amgen$1K
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$24,6709%
  • Speaking & faculty fees$208,33477%
  • Travel & lodging$25,5469%
  • Food & beverage$12,7285%
  • Education$2590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$271,537 in reported general payments places this provider in the 90th percentile of 81 rheumatology providers in Kentucky.

See all rheumatology providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,014,633
Medicare patients
220
Services billed
38,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5012$305,963
Cosentyx Sensoready (2 Pens)Secukinumab19$142,326
Enbrel SureclickEtanercept15$109,262
Humira(Cf) PenAdalimumab15$101,763
RinvoqUpadacitinib11$69,608
BenlystaBelimumab14$67,227
Orencia ClickjectAbatacept11$63,485
MethotrexateMethotrexate Sodium685$13,620
Hydroxychloroquine Sulfate152$4,991
Sulfasalazine128$4,395
Leflunomide93$2,978
Prednisone354$2,684
Febuxostat15$2,428
Mycophenolate Mofetil19$1,736
Leucovorin Calcium50$1,554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$192$305,96312 claims
AbbVieRinvoq$18,116$69,60811 claims
GSKBenlysta$100$67,22714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 81 rheumatology providers in Kentucky.

Other rheumatology in Florence

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →